Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancer

(MedPage Today) -- NEW YORK -- Rucaparib (Rubraca) turned in mixed results for survival outcomes in patients with recurrent ovarian carcinoma, according to an ARIEL3 trial update. There was a benefit for progression-free survival (PFS), as treatment...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news